A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Photo by Dimitri Karastelev on Unsplash

One Antibody Trial Is Halted, While Others Continue

By Kristen Pratt Machado On Oct 28, 2020

An ongoing trial of the antibody bamlanivimab—administered with remdesivir, an antiviral medication—on hospitalized COVID-19 patients has been halted by bamlanivimab’s manufacturer Eli Lilly. The decision was made to stop the trial after evidence showed the therapy had little positive effect on those with serious COVID-19 illness. However, the pharmaceutical company is continuing trials on bamlanivimab in different settings, including evaluating its effect on patients in the earliest stages of COVID-19. Click here to read more.

Kristen Pratt Machado

Kristen Pratt Machado is executive editor for Dimensions of Dental Hygiene and Decisions in Dentistry and director of publishing operations for Belmont Publications, Inc. She has been with Belmont Publications since its inception in 2002.

Growing Your Dental Practice to Multiple Locations: Tips for Success

Youth E-Cigarette Use Is Down, but 3.6 Million Still Use E-Cigarettes